Fig. 5: Revised risk stratification model for Chinese pediatric AML.

a Flow chart of the revised risk stratification model, SCMC-pAML, for Chinese pediatric AML. The model was constructed on top of the European LeukemiaNet (ELN) model, revised to include specific clinically relevant driver alterations established in Chinese pediatric AML. b The revised SCMC-pAML model was used to re-stratify patients into risk groups. Risk groups from the SCMC-pAML model and ELN model are shown on the right and left, respectively. Colors indicate different risk factors, and line width is proportional to the number of cases. The genomic alterations leading to re-stratification are labeled on the right. Numbers in the plot indicate the number of cases in each category. A total of 271 cases with sufficient follow-up information were re-stratified using the SCMC-pAML model and included in survival analysis. c Event-free survival rate estimates for risk groups stratified using the SCMC-pAML (dashed lines) and ELN model (solid lines). The SCMC-pAML model significantly increased the power of risk stratification of Chinese pediatric AML patients, with low- and intermediate-risk patients showing more favorable outcome, and high-risk patients showing worse outcome (log-rank test, P = 2.859E−26).